Article
Absence of copy number gain of EGFR: A possible predictive marker of long-term response to afatinib.
Cancer science - 1 Mar 2023
Nakamura Tomomi, Sato Akemi, Nakashima Chiho, Abe Tomonori, Iwanaga Kentaro, Umeguchi Hitomi, Kawaguchi Atsushi, Sueoka-Aragane Naoko
Abstract excerpt
Treatment efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is diverse even in non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. Extraordinary long-term responses sustained over 3 years among NSCLC patients treated with afatinib, an EGFR-TKI, have been reported, but how to predict such long survivors has not been clarified. A multi-institutional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.